722 related articles for article (PubMed ID: 28619436)
1. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
3. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
4. Tumefactive multiple sclerosis (TMS): A case series of this challenging variant of MS.
Villarreal JV; Abraham MJ; Acevedo JAG; Rai PK; Thottempudi N; Fang X; Gogia B
Mult Scler Relat Disord; 2021 Feb; 48():102699. PubMed ID: 33373797
[TBL] [Abstract][Full Text] [Related]
5. Tumour-like lesions in multiple sclerosis.
Jamroz-Wiśniewska A; Janczarek M; Belniak E; Stelmasiak Z; Bartosik-Psujek H
Neurol Neurochir Pol; 2008; 42(2):161-7. PubMed ID: 18512174
[TBL] [Abstract][Full Text] [Related]
6. Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases.
Vakrakou AG; Tzanetakos D; Evangelopoulos ME; Argyrakos T; Tzartos JS; Anagnostouli M; Andreadou E; Koutsis G; Velonakis G; Toulas P; Gialafos E; Dimitrakopoulos A; Psimenou E; Stefanis L; Kilidireas C
Ther Adv Neurol Disord; 2021; 14():17562864211006503. PubMed ID: 34046086
[TBL] [Abstract][Full Text] [Related]
7. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
8. Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.
Baroncini D; Ghezzi A; Annovazzi PO; Colombo B; Martinelli V; Minonzio G; Moiola L; Rodegher M; Zaffaroni M; Comi G
Mult Scler; 2016 Sep; 22(10):1315-26. PubMed ID: 27230789
[TBL] [Abstract][Full Text] [Related]
9. [Tumefactive demyelinating lesion (TDL)].
Nakajima A; Kawachi I
No Shinkei Geka; 2021 Mar; 49(2):376-382. PubMed ID: 33762460
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.
Ongphichetmetha T; Aungsumart S; Siritho S; Apiwattanakul M; Tanboon J; Rattanathamsakul N; Prayoonwiwat N; Jitprapaikulsan J
Sci Rep; 2024 Jan; 14(1):1426. PubMed ID: 38228919
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and long-term outcome of tumefactive demyelinating lesions in multiple sclerosis.
Totaro R; Di Carmine C; Splendiani A; Torlone S; Patriarca L; Carrocci C; Sciamanna S; Marini C; Carolei A
Neurol Sci; 2016 Jul; 37(7):1113-7. PubMed ID: 27083895
[TBL] [Abstract][Full Text] [Related]
12. Update on disease-modifying therapies for multiple sclerosis.
Vargas DL; Tyor WR
J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
[TBL] [Abstract][Full Text] [Related]
13. Tumefactive MS lesions under fingolimod: a case report and literature review.
Pilz G; Harrer A; Wipfler P; Oppermann K; Sellner J; Fazekas F; Trinka E; Kraus J
Neurology; 2013 Nov; 81(19):1654-8. PubMed ID: 24097813
[TBL] [Abstract][Full Text] [Related]
14. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
15. Isolated tumefactive demyelinating lesions: diagnosis and long-term evolution of 16 patients in a multicentric study.
Siri A; Carra-Dalliere C; Ayrignac X; Pelletier J; Audoin B; Pittion-Vouyovitch S; Debouverie M; Lionnet C; Viala F; Sablot D; Brassat D; Ouallet JC; Ruet A; Brochet B; Taillandier L; Bauchet L; Derache N; Defer G; Cabre P; de Seze J; Lebrun Frenay C; Cohen M; Labauge P
J Neurol; 2015 Jul; 262(7):1637-45. PubMed ID: 25929666
[TBL] [Abstract][Full Text] [Related]
16. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
17. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
Majima H; Ito T; Koyama N
Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
[TBL] [Abstract][Full Text] [Related]
18. Cerebral toxoplasmosis in an MS patient receiving Fingolimod.
Enriquez-Marulanda A; Valderrama-Chaparro J; Parrado L; Diego Vélez J; Maria Granados A; Luis Orozco J; Quiñones J
Mult Scler Relat Disord; 2017 Nov; 18():106-108. PubMed ID: 29141790
[TBL] [Abstract][Full Text] [Related]
19. Different MRI patterns in MS worsening after stopping fingolimod.
Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
[TBL] [Abstract][Full Text] [Related]
20. Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report.
Harirchian MH; Taalimi A; Siroos B
Mult Scler Relat Disord; 2015 Sep; 4(5):400-402. PubMed ID: 26346786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]